Yersinia Diagnostics Market is estimated to be valued at USD 324.6 Mn in 2026 and is expected to reach USD 466.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 324.6 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
5.30% |
2033 Value Projection: |
USD 466.0 Mn |
Yersinia diagnostics is a specialized field with the aim of detection and identification of Yersinia species responsible for infections such as yersiniosis and plague. The market comprises culture-based approaches, PCR, ELISA, serological tests and next-generation sequencing (NGS), used in clinical, food-safety and public-health applications.
The global yersinia diagnostics market is driven by increasing foodborne disease surveillance, growing awareness of zoonotic infections and investments in infectious-disease testing infrastructure. The clinical and commercial relevance of Yersinia diagnostics is further bolstered by increasing demand for rapid pathogen identification and effective outbreak and antimicrobial-resistance management.
Market Dynamics
The global market for yersinia diagnostics is mainly influenced by the increased emphasis on surveillance of foodborne diseases, increased awareness regarding zoonotic infections, and innovations in rapid molecular diagnostics such as multiplex PCR. Other factors contributing to the demand for rapid and precise Yersinia detection include increased investments in infectious-disease preparedness, public-health surveillance, and laboratory infrastructure.
However, the growth of yersinia diagnostics market is limited by factors such as limited clinical awareness, non-specific symptoms, high costs of advanced diagnostic platforms and inadequate laboratory infrastructure in emerging economies. Nevertheless, significant opportunities exist in growth of point-of-care testing, multi-pathogen diagnostic panels, and collaborations to develop affordable, field-deployable solutions present significant opportunities, especially across Asia Pacific, Latin America and Africa.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global yersinia diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., bioMerieux SA, Bio-Rad Laboratories, Inc., Hologic, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, QIAGEN N.V., ELITechGroup, CerTest Biotec S.L., and TestLine Clinical Diagnostics s.r.o.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global yersinia diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global yersinia diagnostics market
Market Segmentation
- Product Type Insights (Revenue, USD Mn, 2021 - 2033)
- Kits and Reagents
- Culture Media
- Instruments and Analyzers
- Controls and Standards
- Others
- Test Type Insights (Revenue, USD Mn, 2021 - 2033)
- Molecular Tests
- Culture Tests
- Serological Tests
- Immunoassays
- Biochemical Tests
- Others
- Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
- Yersiniosis
- Plague
- Yersinia pseudotuberculosis Infection
- Others
- Technology Insights (Revenue, USD Mn, 2021 - 2033)
- Polymerase Chain Reaction (PCR)
- Multiplex PCR
- DNA Probes
- Immunoassay
- Monoclonal Antibodies
- MALDI-TOF Mass Spectrometry
- Sequencing
- Others
- Sample Type Insights (Revenue, USD Mn, 2021 - 2033)
- Stool Samples
- Blood Samples
- Tissue Samples
- Food Samples
- Environmental Samples
- Others
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Clinical Diagnostics
- Food Safety Testing
- Public Health Surveillance
- Veterinary Diagnostics
- Research and Academic Use
- Others
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals and Clinics
- Diagnostic Laboratories
- Public Health Laboratories
- Food Testing Laboratories
- Veterinary Laboratories
- Research and Academic Institutes
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific Inc.
- bioMerieux SA
- Bio-Rad Laboratories, Inc.
- Hologic, Inc.
- Becton, Dickinson and Company
- Hoffmann-La Roche Ltd
- QIAGEN N.V.
- ELITechGroup
- CerTest Biotec S.L.
- TestLine Clinical Diagnostics s.r.o.